TrialArthritis research & therapy2022

Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.

Edward P Stern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.